Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05270824
Other study ID # FUGES-025
Secondary ID
Status Not yet recruiting
Phase Phase 3
First received
Last updated
Start date March 1, 2022
Est. completion date March 1, 2027

Study information

Verified date February 2022
Source Fujian Medical University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Focusing on the clinical question of whether patients with advanced gastric cancer can benefit from immunotherapy, this project intends to detect the degree of CD8+ tumor-infiltrating lymphocyte infiltration in patients with advanced gastric cancer before and after receiving neoadjuvant combined immunotherapy and neoadjuvant therapy alone. To explore the evolving nature of tumor immune response before and after neoadjuvant therapy for gastric cancer, and quantitatively present it through chemical immunohistochemical techniques to achieve a more accurate diagnosis and treatment and improve the long-term efficacy of patients.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 120
Est. completion date March 1, 2027
Est. primary completion date March 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Age from 18 to 75 years 2. Primary gastric adenocarcinoma (papillary, tubular, mucinous, signet ring cell, or poorly differentiated) confirmed pathologically ; 3. CT/MRI, PET-CT, or laparoscopic exploration should be performed before surgery to confirm the diagnosis of stage =cT2 or N+; 4. Patients who have not received other treatments such as surgery, radiotherapy, chemotherapy, targeted therapy or immunotherapy; 5. Performance status of 0 or 2 on Eastern Cooperative Oncology Group scale (ECOG); 6. Estimated survival time was over 3 months; 7. No serious heart, lung and liver dysfunction; no jaundice and gastrointestinal obstruction; no acute infection;; 8. The major organs are functioning normally and meet the following criteria: (1) Blood routine examination should meet the requirements (no blood transfusion within 14 days): 1. HB=100g/L, 2. WBC=3×109/L 3. ANC=1.5×109/L, 4. PLT=100×109/L; (2)Biochemical tests must meet the following criteria: a. BIL <1.5×upper limit of normal (ULN), b. ALT and AST<2.5ULN,GPT=1.5×ULN; c. Cr=1ULN,Ccr >60ml/min 9. Fertile women must have taken a pregnancy test (serum) within 7 days prior to enrollment with negative results and be willing to use an appropriate method of contraception during the trial period and 8 weeks after the last trial drug; For men, they should be surgically sterilized or agree to use the appropriate method of contraception during the trial period and 8 weeks after the last administration of the trial drug 10. Did not participate in other clinical studies before and during treatment 11. Subjects voluntarily joined the study and signed informed consent with good compliance and follow-up Exclusion Criteria: 1. History of other malignant disease within past five years; 2. History of immunodeficiency, including HIV positive, or other acquired congenital immunodeficiency disease, or a history of organ transplantation and allogeneic bone marrow transplantation; 3. Contraindications to surgery and chemotherapy, or whose physical condition and organ function do not allow for major abdominal surgery 4. Distant metastases; 5. Accompanied by severe heart, lung, liver and kidney diseases; neurological and mental diseases; jaundice and accompanied by severe infection; 6. Women during pregnancy or breast-feeding; 7. Patients with high blood pressure that cannot be reduced to the normal range after antihypertensive drug treatment (systolic blood pressure>140 mmHg, diastolic blood pressure>90 mmHg); 8. Suffering from coronary heart disease of grade I or above, arrhythmia (including QTc interval prolongation > 450 ms in men and > 470 ms in women), and cardiac insufficiency; 9. Patients with a clear tendency to gastrointestinal bleeding, including the following conditions: patients with locally active ulcer lesions, fecal occult blood (++), and history of melena and hematemesis within 2 months; patients with abnormal coagulation function (INR> 1.5, APTT>1.5 ULN); 10. Patients with a history of cardiovascular and cerebrovascular diseases who are still taking oral thrombolytics or anticoagulants; 11. Patients with positive urine protein (urinary protein test 2+ or above, or 24-hour urine protein quantitative> 1.0g; 12. Multiple factors affect oral drugs (such as inability to swallow, persistent uncontrollable nausea and vomiting, chronic diarrhea and intestinal obstruction, etc.); 13. Those who have allergic reactions to the drugs in this study; 14. The researcher believes that it is not suitable for inclusion.

Study Design


Intervention

Combination Product:
radical surgery after neoadjuvant immunotherapy
A total or distal gastrectomy with D2 lymph node dissection was done depending on the tumor location after neoadjuvant immunotherapy.
radical surgery after neoadjuvant chemotherapy
A total or distal gastrectomy with D2 lymph node dissection was done depending on the tumor location after neoadjuvant immunotherapy.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Fujian Medical University

Outcome

Type Measure Description Time frame Safety issue
Primary The number of CD8+ tumor-infiltrating lymphocytes in tumor tissue and adjacent tissue before and after treatment Changes in the number of CD8+ tumor-infiltrating lymphocytes in the tumor and adjacent tissues of the experimental group before and after the surgery compared with the control group. 6 months
Secondary Objective response rate (ORR) Complete response (CR) + partial response (PR) 6 months
Secondary Disease-free survival (DFS) Time from study entry to disease recurrence or patient death due to disease progression 2 years
Secondary Overall survival (OS) Time from study entry to death from any cause. 2 years
Secondary Therapeutic drug safety Adverse events (AEs), serious adverse events (SAEs), drug-related AEs, SAEs, and class-specific AEs (eg, hypertension, proteinuria, and hand-foot syndrome) 6 months
Secondary Surgical safety R0 resection rate, operative mortality, surgical complications (bleeding, anastomotic leakage, incision infection), reoperation rate, hospital stay, etc. 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT05545293 - Prospective Study on Double-Stapling End-to-End Gastroduodenostomy Billroth-I Anastomosis in Laparoscopy-Assisted Surgery for Locally Advanced Distal Gastric Cancers
Completed NCT04808791 - iTTo for Treatment Naive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Phase 2
Recruiting NCT05620732 - Treatment of Advanced Malignant Solid Tumors With Claudin18.2CAR-T N/A
Recruiting NCT05221775 - Safety of XELOX Combined With GLS-010 and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients Phase 1
Completed NCT05334849 - Prospectively Predict the Immunotherapy Response of Gastric Cancer Based on Circulating Exosomal LncRNA-GC1 Biopsy
Not yet recruiting NCT05313906 - RC48 Plus AK105 and Cisplatin in Advanced Gastric Cancer Phase 2
Completed NCT00192088 - A Study of Pemetrexed Plus Oxaliplatin as First Line Therapy in Advanced Gastric Carcinoma Phase 2
Terminated NCT04718402 - A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Gastric Carcinoma Phase 1
Active, not recruiting NCT01534546 - Phase III Study to Compare Perioperative Chemotherapy of Oxaliplatin Combined With S-1(SOX) Versus SOX or Oxaliplatin With Capecitabine (XELOX) as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma With D2 Dissection Phase 3
Recruiting NCT04739202 - Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST) Phase 2
Completed NCT05997524 - Clinical Efficacy of Trastuzumab in Combination With Capecitabine and Oxaliplatin for the Treatment of HER2-positive Advanced Gastric Cancer. Phase 2
Recruiting NCT06264921 - A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors Phase 1
Recruiting NCT05805956 - IMM2902 in Patients With Advanced Solid Tumors Expressing HER2 Phase 1/Phase 2
Not yet recruiting NCT02163291 - Study on Neoadjuvant Chemotherapy for Advanced Gastric Cancer Phase 2
Recruiting NCT04704661 - Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial Phase 1
Recruiting NCT06028737 - Total Neoadjuvant Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer Phase 2/Phase 3
Active, not recruiting NCT04491942 - Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer Phase 1
Recruiting NCT05969860 - At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer Phase 2
Active, not recruiting NCT04535401 - Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines Phase 1
Recruiting NCT05226169 - Efficacy and Safety oF FErric CarboxymalTose in Patients With Advanced Gastric Cancer(EFFECT-AGC) Phase 3